Beulah N. Ji

GlaxoSmithKline R&D
Uxbridge, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis.

Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis.

Journal: Kidney international

Published: May 14, 2025

Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data.

Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data.

Journal: Lupus science & medicine

Published: September 28, 2022

Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.

Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.

Journal: American journal of kidney diseases : the official journal of the National Kidney Foundation

Published: October 03, 2021

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.

Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.

Journal: RMD open

Published: May 25, 2021

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.

Journal: Arthritis research & therapy

Published: May 14, 2021

A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.

A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.

Journal: Kidney international

Published: March 26, 2021

Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationale.

Investigation of the Clinical, Radiological and Biological Factors Associated with Disease Progression, Phenotypes and Endotypes of COPD in China (COMPASS): study design, protocol and rationale.

Journal: ERJ open research

Published: March 18, 2021

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.

Journal: RMD open

Published: February 12, 2021

Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.

Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: December 03, 2020

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

Journal: The New England journal of medicine

Published: September 16, 2020

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus.

Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus.

Journal: Clinical pharmacology in drug development

Published: July 27, 2020

Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial.

Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial.

Journal: The Lancet. Rheumatology

Published: June 25, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026